Arthritis News and Research

Latest Arthritis News and Research

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Pregnancy-related foot changes may contribute to women's increased risk for arthritis

A new University of Iowa study confirms what many women have long suspected - that pregnancy permanently changes the size and shape of a woman's feet.

3 Mar 2013

Tooth loss due to periodontal disease is more prevalent among postmenopausal women

Postmenopausal women who have smoked are at much higher risk of losing their teeth than women who never smoked, according to a new study published and featured on the cover of the Journal of the American Dental Association by researchers at the University at Buffalo.

2 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

$Bisphosphonate link to nonhealing fractures strengthened$

Bisphosphonate link to nonhealing fractures strengthened

US scientists have identified a safety signal between bisphosphonate use and nonhealing femoral fractures, possibly due to the rare side effect, atypical femur fracture.

1 Mar 2013

Not all acne bacteria trigger pimples: Study

The bacteria that cause acne live on everyone's skin, yet one in five people is lucky enough to develop only an occasional pimple over a lifetime.

1 Mar 2013

Double-jointed teens at risk for later pain

Adolescents who have hypermobile joints or are “double jointed” are more likely to develop moderate to severe joint pain in later years, show study findings.

28 Feb 2013

Hypermobile children at greater risk for joint pain as they get older

A prospective study by U.K. researchers found that adolescents who are double-jointed—medically termed joint hypermobility—are at greater risk for developing musculoskeletal pain as they get older, particularly in the shoulders, knees, ankles and feet. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that children with joint hypermobility are approximately twice as likely to develop pain at these joints.

28 Feb 2013

Mutant HSP70i protein may offer potent treatment opportunities for vitiligo

Loyola University Chicago Stritch School of Medicine researchers have developed a genetically modified protein that dramatically reverses the skin disorder vitiligo in mice, and has similar effects on immune responses in human skin tissue samples.

28 Feb 2013

Adolescents with joint hypermobility more likely to develop musculoskeletal pain

A prospective study by U.K. researchers found that adolescents who are double-jointed-medically termed joint hypermobility-are at greater risk for developing musculoskeletal pain as they get older, particularly in the shoulders, knees, ankles and feet.

28 Feb 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.

25 Feb 2013

Researchers map complex interactions of proteins that control inflammation

Inflammatory response plays a major role in both health protection and disease generation. While the symptoms of disease-related inflammatory response have been know, scientists have not understood the mechanisms that underlie it.

25 Feb 2013

Study finds bariatric surgery does not reduce long-term medical costs

Research disputes widely-held beliefs that the weight-loss operations cut the need for treatments and medicine after patients shed pounds.

22 Feb 2013

New mouse model can advance research on iPS cells to next step

VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Allergan receives FDA approval for Natrelle 410 breast implant

The U.S. Food and Drug Administration today approved the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. Natrelle 410 implants are manufactured by Allergan, Inc.

20 Feb 2013

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

A study by a leading Alzheimer's researcher at the University of Kentucky provides new evidence that will help researchers home in on the molecular mechanisms involved in inflammation of the central nervous system (CNS) and aid drug-development strategies for treating inflammatory neurological diseases.

20 Feb 2013

Researchers suggest that fibromyalgia is a spectrum disorder

Researchers have determined that fibromyalgia prevalence is 2.1% of the general population in Germany. Results appearing in Arthritis Care & Research, a journal published by Wiley on behalf of the American College of Rheumatology (ACR), suggest that fibromyalgia is a spectrum disorder rather than a categorical illness.

20 Feb 2013